Scientists are making strides in the hunt for treatments that can slow or stop Parkinson's disease itself, moving beyond therapies that only manage its symptoms. This work focuses on identifying early warning signs in the body and targeting naturally resilient brain pathways.
Central to this effort is the search for reliable biomarkers. Researchers aim to find measurable indicators in areas like blood that could signal the presence of Parkinson's or the risk of developing it long before major symptoms appear. "This is where we want to move with Parkinson's," explained Dr. Michael Henderson, a neurodegenerative science professor. He likens it to using high cholesterol as a biomarker for heart disease, allowing for preventative intervention. Alongside this, teams are investigating why some brain regions withstand Parkinson's pathology better than others. They have identified specific molecules linked to this resilience and have found a compound that targets one, successfully reducing disease pathology in model systems. "We're really excited about that," Henderson said.
Currently, available treatments for Parkinson's, which affects more than 10 million people globally, address symptoms like tremors and stiffness but do not alter the disease's progressive course. The discovery of compounds that target protective pathways represents a significant shift toward developing a true disease-modifying treatment. The ultimate goal is a therapy that can "slow or stop the progression of the disease," Henderson noted.
To accelerate this work, institutes are engaged in initiatives like the International Linked Clinical Trial Initiative, which repurposes medications already approved for other conditions for Parkinson's trials, saving considerable time and resources. Furthermore, large-scale studies like the West Michigan Neurodegenerative Diseases Program (MiND) are recruiting participants to study genetic and epigenetic factors behind the disease. While Henderson cautions that the path is long and complex, the coordinated focus on early detection and protective biology offers a hopeful outlook for eventually changing the trajectory of Parkinson's disease for patients.